When the Mayo Clinic developed a test for optimizing treatment of gastrointestinal problems related to autoimmune disorders, Prometheus Laboratories sued for patent infringement. Prometheus held two patents on a similar methodology for physicians who prescribe thiopurine drugs to treat patients with autoimmune diseases, in order to assess whether a particular dosage level is optimal. These patents applied natural laws governing the relationships between the blood concentration of certain thiopurine metabolites and the likelihood of side effects or ineffectiveness of the drug dosage.
A longstanding principle of patent law is that "laws of nature, natural phenomena, and abstract ideas" are not patentable. Diamond v. Diehr, 450 U.S. 175 (1981). But finding where natural phenomena ends and patentable human creativity begins is not easy. Most inventions rely on "laws of nature, natural phenomena, and abstract ideas" to accomplish their goals. The U.S. Court of Appeals for the Federal Circuit, which handles patent appeals, upheld Prometheus's patents.
The United States Supreme Court unanimously reversed, and invalidated these patents. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 2012 U.S. LEXIS 2316 (Mar. 20, 2012). The Court agreed with amicus briefs opposing the patents, which had been filed by medical societies (including one foreign medical association asserting that methods of medical treatment are not patentable in most of Western Europe).
Prometheus, for its part, insisted that denying patent protection will impede innovation by removing the incentive to fund expensive diagnostic research. It is our strong patent system that "ha[s] made the United States the world leader in this field," Prometheus argued, and such innovation requires patent protection to continue.
The Obama Administration argued in favor of patentability, but urged the Court to find that these particular patents failed to satisfy the requirement of novelty. In other words, the Obama Administration would have supported Prometheus's patents if they had been more original. But the Court rejected these arguments by Prometheus and the government, and instead opted for declaring this type of invention to be entirely unpatentable, no matter how original it may be.
"Einstein could not patent his celebrated law that E=mc2; nor could Newton have patented the law of gravity. Such discoveries are manifestations of . . . nature, free to all men and reserved exclusively to none," the Court held, quoting prior rulings for that statement. Putting aside whether Einstein was the one who first discovered E=mc2 -- or whether that formula is even an accurate description of nature -- the Court removed from patentability discoveries and inventions that consist primarily of natural phenomenon.
Unanimous decisions like this are guideposts for future disputes, and one sentence in the opinion may be helpful to challenging the recent federal law awarding patent rights to the first who files rather than to the first who invents. Justice Breyer, writing for the Court, discussed the patent system in terms of "rewarding with patents those who discover," and thus not merely those who file. That may be a silver lining in this decision.